Using recombinant endostatin and platinum-based radiotherapy for non-small cell lung cancer

Abstract

Author(s): Birendra Kumar Sahu, Pranjali Verma, Jitendra Sinha

Non-small Cell Lung Cancer (NCLC) is the predominant form of lung cancer, representing the primary cause of cancer-related mortality on a global scale. In recent decades, significant research has been conducted on tumor angiogenesis in treating NCLC, owing to its pivotal role in advancing cancer. Numerous anti-angiogenic pharmaceuticals, including Recombinant Endostatin (RE), have undergone extensive assessment in preclinical and clinical settings, yielding varied outcomes that frequently fall short of expectations. Nevertheless, there is a growing fascination with RE owing to its capacity to induce a circulatory normalizing window, thereby potentially enhancing the therapeutic effectiveness of the conventional treatment for NCLC. This work aimed to assess the potential benefits of RE in enhancing the effectiveness and safety of Platinumbased Radiotherapy (PRT) when administered through intravenous and pulmonary infusions for patients with stage IIIA/B-NCLC. This paper presents a comprehensive review of both experimental and clinical investigations that have examined the combined administration of REPRT as a therapeutic approach for NCLC treatment. Out of the total sample size of 14 individuals who were assessed, the treatment's combined effectiveness is 77.6%. This percentage indicates a substantial proportion of positive results about the therapeutic intervention. The disease control rate, encompassing patients who display complete or partial responses, exhibits a noteworthy rise of 89.6%. The results underscores the effectiveness of RE-PRT in successfully arresting or reversing the advancement of the NCLC

Share this article